Screener
Syndax Pharmaceuticals SNDX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 471,177 | 528,081 |
| Property and equipment, net | 177 | 181 |
| Right-of-use asset, net | 1,212 | 1,342 |
| Restricted cash | 102 | 102 |
| Total assets | $472,668 | $529,706 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $10,843 | $16,580 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's restricted cash?
- Syndax Pharmaceuticals (SNDX) reported restricted cash of $102K in Q1 2026.
- How has Syndax Pharmaceuticals's restricted cash changed year-over-year?
- Syndax Pharmaceuticals's restricted cash decreased by 53.0% year-over-year, from $217K to $102K.
- What is the long-term trend for Syndax Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's restricted cash has grown at a -2.4% compound annual growth rate (CAGR), from $115K to $102K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Syndax Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude